Potential of the trifunctional bispecific antibody Surek depends on dendritic cells: Rationale for a new approach of tumor immunotherapy

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 54-61

  Eissler, Nina ^a   Mysliwietz, Josef ^a   Deppisch, Nina ^a   Ruf, Peter ^b   Lindhofer, Horst ^b,c   Mocikat, Ralph ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TRION Research   (Germany)

^c TRION Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; DENDRITIC CELL VACCINE; SUREK; UNCLASSIFIED DRUG; CD69 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; IN VITRO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN; CELL STRAIN B16 EPCAM; COCULTURE; FLUORESCENCE ACTIVATED CELL SORTING; LYMPHOCYTE PROLIFERATION;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 84877095509     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00140     Document Type: Article

References (37)

1. Banchereau J, et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
2. Melief CJ. (2008) Cancer immunotherapy by dendritic cells. Immunity. 29:372-83.
3. Valone FH, et al. (2001) Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 7 Suppl 2:S53-S61.
4. Engleman EG. (2003) Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30:23-29.
5. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H. (1997) Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res. 57:2346-2349.
6. Selmayr M, et al. (1999) Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther. 6:778-784.
7. Selmayr M, Menzel H, Kremer JP, Thierfelder S, Mocikat R. (2000) B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity. Cancer Gene Ther. 7:501-506.
8. Graf N, Adam C, Mocikat R. (2003) Persistence of xenogenized vaccine cells in vivo. Int. J. Cancer. 105:217-220.
9. Kronenberger K, et al. (2002) Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. Blood. 99:1327-1331.
10. Peipp M, Valerius T. (2002) Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. 30:507-511.
11. Chames P, Baty D. (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 1:539-547.
12. Zeidler R, et al. (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163:1246-1252.
13. Zeidler R, et al. (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer. 83:261-266.
14. Ruf P, Lindhofer H. (2001) Induction of a longlasting antitumor immunity by a trifunctional bispecific antibody. Blood. 98:2526-2534.
15. Eißler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. (2012) Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 72:3958-3966.
16. Haraguchi M, et al. (1994) Isolation of GD3 synthase gene by expression cloning of GM3 alpha- 2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 91:10455-10459.
17. Schrama D, et al. (2004) Shift from systemic to site-specific memory by tumor-targeted IL-2. J. Immunol. 172:5843-5850.
18. Strehl J, et al. (1999) Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Int. J. Cancer. 83:113-120.
19. Ruf P, et al. (2004) Two new trifunctional antibodies for the therapy of human malignant melanoma. Int. J. Cancer. 108:725-732.
20. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas: implications for a single-step purification of bispecific antibodies. J. Immunol. 155:219-225.
21. Björk P, et al. (1993) Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J. Biol. Chem. 268:24232-41.
22. Ruf P, et al. (2012) Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. J. Transl. Med. 10:219.
23. Lindhofer H, Hess J, Ruf P. (2011) Triomab® antibodies for cancer therapy. In: Bispecific Antibodies. Kontermann R. (ed.). Springer, Heidelberg, pp. 289-312.
24. Hess J, Ruf P, Lindhofer H. (2012) Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol. 8:73-85.
25. Heiss MM, et al. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int. J. Cancer. 127:2209-2221.
26. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions. MAbs. 2:129-136.
27. Ragupathi G, et al. (2003) Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9:5214-5220.
28. Navid F, Santana VM, Barfield RC. (2010) Anti- GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets. 10:200-209.
29. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Röcken M. (2000) Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res. 60:1515-1520.
30. Schüler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. (1999) T helper cell type 1- associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4- deficient mice. J. Exp. Med. 189:803-810.
31. Lüking C, et al. (2008) Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression. Int. J. Cancer. 122:2280-2285.
32. Heiss M, et al. (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int. J. Cancer. 117:435-443.
33. Kiewe P, et al. (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res. 12:3085-3091.
34. Boussiotis VA, et al. (1994) Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 266:1039-1042.
35. Linsley PS, Ledbetter JA. (1993) The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191-212.
36. Adam C, Mysliwietz J, Mocikat R. (2007) Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J. Transl. Med. 5:16.
37. Zobywalski A, et al. (2007) Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5:18.